A Phase 3 interventional study of Albumin-bound paclitaxel and Paclitaxel in Non-Small Cell Lung Carcinoma, sponsored by Celgene. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 11 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Carcinoma, Non-Small-Cell Lung.
Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 3 that started in 2007, is one of 8 in phase 3, and was the 6th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
People's Hospital of Quzhou · Sites in China
Ages 18–75
Fox Chase Cancer Center · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
German Cancer Research Center
Ages 18+ · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 33 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,052 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 47 interventional studies. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 107 interventional ones that give a count, is one of 2 that started in 2007, is one of 27 in phase 3, and was the 13th registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
1 of the studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or non-pregnant and non-lactating female, and equal or greater than age 18
Patient has the following blood counts at baseline:
Patient has the following blood chemistry levels at baseline:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m\^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg\*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
Drug: Albumin-bound paclitaxel · Drug: Carboplatin
Participants received 200 mg/m\^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg\*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
Drug: Paclitaxel · Drug: Carboplatin
Administered by intravenous infusion.
Also known as: ABI-007, ABRAXANE®, nab®-paclitaxel
Administered by intravenous infusion.
Also known as: Taxol®
Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment
Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions).
Time frame: Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.
Progression-free Survival by Blinded Radiology Assessment
Progression free survival time was defined as the time from the day of randomization to the start of disease progression or death (any cause), whichever occurred first, based on the blinded radiological review response assessment. Progressive disease was defined as a ≥ 20% increase in the SLD of target lesions, taking as reference the nadir SLD recorded since the treatment started, or the presence of one or more new lesions, or the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesion(s). Participants who did not have disease progression or had not died were censored at the last visit they were documented as progression free. If palliative radiotherapy or surgery at lesion sites occurred, the participant was censored at the last date without documented progression prior to radiotherapy or surgery. In follow-up, participants who began new therapy prior to progression were censored at the last documented date as progression-free.
Time frame: Assessed every 6 weeks until progression or death, up to 38 months
Overall Participant Survival
Overall survival was defined as the time from the day of randomization to participant death (due to any cause), as assessed by post study follow-up performed monthly for 6 months and every 3 months thereafter for 12 months. All participants who were lost to the follow-up prior to the end of the trial or who completed the 18 month follow up phase were censored at last known time the participant was alive.
Time frame: Up to 38 months
Percentage of Participants With Controlled Disease
Controlled disease was defined as the percentage of participants with stable disease for ≥ 16 weeks or confirmed complete or partial overall response, based on blinded radiological assessment. Stable disease was defined as neither sufficient shrinkage of target lesions to qualify for Partial Response, nor sufficient increase to qualify for Progressive Disease, or the persistence of one or more non-target lesions not qualifying for Complete Response or Progressive Disease.
Time frame: Assessed every 6 weeks, up to 22 months
Duration of Response in Responding Patients
Duration of response was assessed by progression free survival for participants who achieved a confirmed complete response or partial response based on blinded radiological assessment.
Time frame: Assessed every 6 weeks, up to 38 months
Number of Participants With Adverse Events (AEs)
A Treatment-emergent AE was any AE that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. Treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
Time frame: Up to 38 months
Pharmacokinetic (PK) Parameters
Time frame: Blood samples for PK analyses were taken during Cycle 1 at 0.25, 3.5 and 24 hours post-infusion.
SPARC Status and Correlation With Overall Survival
The expression and cellular distribution of Secreted Protein Acidic and Rich in cysteine (SPARC) in biopsies of lung tumor was examined by immunohistochemistry using a 2 antibody system by an approved central laboratory and analyzed by 2 pathologists. The following tissue components were scored: tumor cells, fibroblasts, inflammatory cells, acellular stroma/matrix, and blood vessels. To classify participants into "high-SPARC" and "low-SPARC" groups, an average z-score was calculated across variables and classified "high-SPARC" (average z-scores ≥0) and "low-SPARC" (average z-scores \<0) groups. SPARC status was then correlated with overall survival (the time from the day of randomization to participant death due to any cause).
Time frame: Archival tissue samples were used for SPARC analysis. Survival was assessed for up to 38 months.
Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment, by Histology
Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions). Histology was determined at the time of primary diagnosis.
Time frame: Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.
Maximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin
The maximal degree of anemia (and myelosuppression) was assessed by the overall nadir of hemoglobin levels based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
Time frame: 38 months
Maximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count
The maximal degree of neutropenia (and myelosuppression) was assessed by the overall nadir of absolute neutrophil count (ANC) based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
Time frame: 38 months
Maximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count
The maximal degree of thrombocytopenia (and myelosuppression) was assessed by the overall nadir of platelet count based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
Time frame: 38 months
Time to Improvement of ≥ Grade 3 Treatment Related Peripheral Neuropathy
Peripheral neuropathy was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. Improvement in peripheral neuropathy was evaluated as: * Time to improvement of grade 3 or higher peripheral neuropathy by at least one grade; * Time to improvement of grade 3 or higher peripheral neuropathy to grade 1. Time to improvement was defined as the time from the first occurrence of grade 3 or higher treatment related neuropathy to improvement, as defined. Participants not experiencing improvement were censored at the last time the participant was evaluated for adverse events.
Time frame: 38 months
| Milestone | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Started | 521 | 531 |
| Treated | 514 | 524 |
| Biomarker population | 35 | 36 |
| Completed | 275 | 265 |
| Not completed | 246 | 266 |
| Withdrew: Still on treatment | 3 | 0 |
| Withdrew: Unacceptable toxicity | 61 | 62 |
| Withdrew: Adverse event | 20 | 24 |
| Withdrew: Physician decision | 86 | 99 |
| Withdrew: Protocol deviation | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 65 | 67 |
| Withdrew: Excluded prior to treatment | 7 | 7 |
| Withdrew: Paclitaxel not available | 0 | 2 |
Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions).
| percentage of participants | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment | 33 (28.6 to 36.7) | 25 (21.2 to 28.5) |
Progression free survival time was defined as the time from the day of randomization to the start of disease progression or death (any cause), whichever occurred first, based on the blinded radiological review response assessment. Progressive disease was defined as a ≥ 20% increase in the SLD of target lesions, taking as reference the nadir SLD recorded since the treatment started, or the presence of one or more new lesions, or the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesion(s). Participants who did not have disease progression or had not died were censored at the last visit they were documented as progression free. If palliative radiotherapy or surgery at lesion sites occurred, the participant was censored at the last date without documented progression prior to radiotherapy or surgery. In follow-up, participants who began new therapy prior to progression were censored at the last documented date as progression-free.
| months | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Progression-free Survival by Blinded Radiology Assessment | 6.3 (5.6 to 7.0) | 5.8 (5.6 to 6.7) |
Overall survival was defined as the time from the day of randomization to participant death (due to any cause), as assessed by post study follow-up performed monthly for 6 months and every 3 months thereafter for 12 months. All participants who were lost to the follow-up prior to the end of the trial or who completed the 18 month follow up phase were censored at last known time the participant was alive.
| months | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Overall Participant Survival | 12.1 (10.8 to 12.9) | 11.2 (10.3 to 12.6) |
Controlled disease was defined as the percentage of participants with stable disease for ≥ 16 weeks or confirmed complete or partial overall response, based on blinded radiological assessment. Stable disease was defined as neither sufficient shrinkage of target lesions to qualify for Partial Response, nor sufficient increase to qualify for Progressive Disease, or the persistence of one or more non-target lesions not qualifying for Complete Response or Progressive Disease.
| percentage of participants | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Percentage of Participants With Controlled Disease | 53 (48.3 to 56.9) | 49 (44.7 to 53.2) |
Duration of response was assessed by progression free survival for participants who achieved a confirmed complete response or partial response based on blinded radiological assessment.
| months | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Duration of Response in Responding Patients | 9.6 (8.3 to 10.8) | 9.5 (8.1 to 11.0) |
A Treatment-emergent AE was any AE that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. Treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
| participants | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| At least 1 AE | 483 | 504 |
| At least 1 grade 3 or higher AE | 360 | 355 |
| At least 1 treatment-related AE | 469 | 481 |
| At least 1 treatment-related grade 3 or higher AE | 321 | 315 |
| At least 1 serious AE | 93 | 80 |
| At least 1 treatment-related serious AE | 37 | 30 |
| At least 1 AE with taxane permanently discontinued | 80 | 84 |
| At least 1 AE with action of taxane dosage reduced | 237 | 120 |
| At least 1 AE with action of taxane interrupted | 0 | 5 |
| At least 1 AE with action of taxane delayed | 365 | 214 |
No measurements were reported for this outcome.
The expression and cellular distribution of Secreted Protein Acidic and Rich in cysteine (SPARC) in biopsies of lung tumor was examined by immunohistochemistry using a 2 antibody system by an approved central laboratory and analyzed by 2 pathologists. The following tissue components were scored: tumor cells, fibroblasts, inflammatory cells, acellular stroma/matrix, and blood vessels. To classify participants into "high-SPARC" and "low-SPARC" groups, an average z-score was calculated across variables and classified "high-SPARC" (average z-scores ≥0) and "low-SPARC" (average z-scores \<0) groups. SPARC status was then correlated with overall survival (the time from the day of randomization to participant death due to any cause).
| participants | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| High-SPARC | 17 (3.3 to 23.1) | 22 (2.3 to 28.0) |
| Low-SPARC | 18 (3.7 to 24.9) | 14 (4.7 to 22.3) |
Antitumor response was defined as the percentage of participants who achieved an objective response (Confirmed Response \[CR\] or Partial Response \[PR\]), confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met. Response was based on the blinded radiological review using Response Evaluation Criteria in Solid Tumors (RECIST) response guidelines, Version 1.0. A complete response was defined as a disappearance of all target and non-target lesions and no new lesions. Partial response was defined as ≥ 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, and the persistence of one or more non-target lesions not qualifying for CR or Progressive Disease (the "unequivocal progression" of existing non-target lesion(s) or appearance of one or more new lesions). Histology was determined at the time of primary diagnosis.
| percentage of participants | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Carcinoma/Adenocarcinoma [254, 264] | 26 | 27 |
| Squamous Cell Carcinoma [229, 221] | 41 | 24 |
| Large Cell Carcinoma [N=9, 13] | 33 | 15 |
| Other [N=29, 33] | 24 | 15 |
The maximal degree of anemia (and myelosuppression) was assessed by the overall nadir of hemoglobin levels based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
| g/L | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Maximal Degree of Anemia Based on Clinical Laboratory Values for Hemoglobin | 90.0 ± 17.19 | 103.9 ± 16.90 |
The maximal degree of neutropenia (and myelosuppression) was assessed by the overall nadir of absolute neutrophil count (ANC) based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
| × 10^9/L | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Maximal Degree of Neutropenia Based on Clinical Laboratory Values of Absolute Neutrophil Count | 1.39 ± 1.721 | 1.26 ± 1.366 |
The maximal degree of thrombocytopenia (and myelosuppression) was assessed by the overall nadir of platelet count based on clinical laboratory measurements graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.
| × 10^9/L | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Maximal Degree of Thrombocytopenia Based on Clinical Laboratory Values of Platelet Count | 114.9 ± 82.13 | 136.6 ± 81.91 |
Peripheral neuropathy was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. Improvement in peripheral neuropathy was evaluated as: * Time to improvement of grade 3 or higher peripheral neuropathy by at least one grade; * Time to improvement of grade 3 or higher peripheral neuropathy to grade 1. Time to improvement was defined as the time from the first occurrence of grade 3 or higher treatment related neuropathy to improvement, as defined. Participants not experiencing improvement were censored at the last time the participant was evaluated for adverse events.
| days | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| Improvement by ≥1 grade | 24.0 (15.0 to NA) | 26.0 (15.0 to 38.0) |
| Improvement to grade 1 | 38.0 (19.0 to NA) | 104.0 (40.0 to 169.0) |
Collected over Up to 38 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Albumin-bound Paclitaxel + Carboplatin | — | 93/514 (18.1%) | 483/514 (94%) |
| Paclitaxel + Carboplatin | — | 80/524 (15.3%) | 499/524 (95.2%) |
| Event | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 19/514 | 3/524 |
| PneumoniaInfections and infestations | 14/514 | 11/524 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/514 | 8/524 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/514 | 6/524 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/514 | 5/524 |
| Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders | 3/514 | 4/524 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/514 | 3/524 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/514 | 1/524 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/514 | 1/524 |
| Cerebral infarctionNervous system disorders | 2/514 | 0/524 |
| Event | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 287/514 | 312/524 |
| NeutropeniaBlood and lymphatic system disorders | 260/514 | 250/524 |
| AnaemiaBlood and lymphatic system disorders | 225/514 | 109/524 |
| ThrombocytopeniaBlood and lymphatic system disorders | 208/514 | 122/524 |
| Peripheral sensory neuropathyNervous system disorders | 136/514 | 209/524 |
| NauseaGastrointestinal disorders | 140/514 | 130/524 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 65/514 | 129/524 |
| FatigueGeneral disorders | 126/514 | 120/524 |
| Neuropathy peripheralNervous system disorders | 104/514 | 118/524 |
| LeukopeniaBlood and lymphatic system disorders | 97/514 | 91/524 |
| Age, Continuous(years) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Mean | 59.5 ± 9.14 | 59.7 ± 9.53 | 59.6 ± 9.33 |
| Sex: Female, Male(Participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Female | 129 | 134 | 263 |
| Male | 392 | 397 | 789 |
| Race/Ethnicity, Customized(participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Asian | 79 | 80 | 159 |
| Black, of African Heritage | 12 | 8 | 20 |
| North American Indian or Alaska Native | 1 | 0 | 1 |
| White, Non Hispanic and Non Latino | 416 | 433 | 849 |
| White, Hispanic or Latino | 11 | 5 | 16 |
| Other | 2 | 5 | 7 |
| Region of Enrollment(participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| United States | 63 | 58 | 121 |
| Canada | 21 | 23 | 44 |
| Australia | 5 | 9 | 14 |
| Japan | 74 | 75 | 149 |
| Russian Federation | 238 | 231 | 469 |
| Ukraine | 120 | 135 | 255 |
| Smoking status(participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Never smoked | 137 | 144 | 281 |
| Smoked and quit smoking | 168 | 148 | 316 |
| Smoked and currently smokes | 214 | 234 | 448 |
| Missing | 2 | 5 | 7 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| 0 (Fully active) | 133 | 113 | 246 |
| 1 (Restrictive but ambulatory) | 385 | 416 | 801 |
| 2 (Ambulatory but unable to work) | 3 | 2 | 5 |
| Time from Primary Diagnosis to Study Entry(months) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| Mean | 4.3 ± 17.12 | 4.3 ± 16.09 | 4.3 ± 16.60 |
| Stage at Primary Diagnosis(participants) | Albumin-bound Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|
| I | 16 | 20 | 36 |
| II | 18 | 24 | 42 |
| IIIa | 22 | 24 | 46 |
| IIIb | 135 | 116 | 251 |
| IV | 325 | 344 | 669 |
| Unknown | 5 | 3 | 8 |
4 further baseline measures are reported on the registry.
Ran from Nov 2007 to primary completion in Oct 2009, 23 months.
Results were first posted in Aug 2013, 3 years 10 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel
Carcinoma, Non-Small-Cell Lung →